Oral bioavailability of ATP after prolonged administration

British Journal of Nutrition

Volumn 105, Issue 3, 2011, Pages 357-366

  Coolen, Erik J C M ^a   Arts, Ilja C W ^a   Bekers, Otto ^b   Vervaet, Chris ^c   Bast, Aalt ^a   Dagnelie, Pieter C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Human studies; Oral ATP administration

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CREATINE KINASE; CREATININE; LACTATE DEHYDROGENASE; PLACEBO; URIC ACID;

ADAPTATION; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PELLET; DRUG SAFETY; ENTERIC COATED TABLET; FEMALE; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN EXPERIMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; SINGLE DRUG DOSE; SUPPLEMENTATION; TREATMENT DURATION; URIC ACID BLOOD LEVEL;

ADENOSINE TRIPHOSPHATE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, PURINERGIC; URIC ACID; YOUNG ADULT;

ANIMALIA;

EID: 79951670096     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114510003570     Document Type: Article

References (44)

1. 0-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112, 358-404. (Pubitemid 44486409)
2. Burnstock G (2006) Purinergic signalling. Br J Pharmacol 147, Suppl. 1, S172-S181. (Pubitemid 43077275)
3. Burnstock G (2008) Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 7, 575-590. (Pubitemid 351927723)
4. Raju NC, Eikelboom JW & Hirsh J (2008) Platelet ADP-recep-tor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med 5, 766-780.
5. 0-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92, 321-328. (Pubitemid 30117735)
6. 0-triphosphate infusions on the nutritional status and survival of preterminal cancer patients. Antican-cer Drugs 20, 625-633.
7. Mathieu P, Richard M & Vignon E (1988) Intra-muscular diffusion and efficacy of Atepadene in non-specific back pain. Rhumatologie 40, 8.
8. De Sezeand S & Bordier P (1987) Randomised double-blind placebo-controlled trial of Atepadene in non-specific back pain. La Gazette Medicale 90, 62-66. (Pubitemid 17139186)
9. Bannwarth B, Allaert FA, Avouac B, et al. (2005) A randomized, double-blind, placebo controlled study of oral adeno-sine triphosphate in subacute low back pain. J Rheumatol 32, 1114-1117. (Pubitemid 40828087)
10. Rossignol M, Allaert FA, Rozenberg S, et al. (2005) Measuring the contribution of pharmacological treatment to advice to stay active in patients with subacute low-back pain: a randomised controlled trial. Pharmacoepidemiol Drug Saf 14, 861-867. (Pubitemid 43056112)
11. 0-triphosphate (ATP) are not bioavailable: a randomized, placebo-controlled cross-over study in healthy humans. (In the Press).
12. Kichenin K, Seman M, Decollogne S, et al. (2000) Chronic oral administration of ATP modulates nucleoside transport and purine metabolism in rats. J Pharmacol Exp Ther 294, 126-133. (Pubitemid 30434678)
13. Pastor-Anglada M, Errasti-Murugarren E, Aymerich I, et al. (2007) Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling. J Physiol Biochem 63, 97-110. (Pubitemid 47180835)
14. Huyghebaert N, Vermeire A & Remon JP (2005) In vitro evaluation of coating polymers for enteric coating and human ileal targeting. Int J Pharm 298, 26-37. (Pubitemid 40828326)
15. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. (1997) The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 99, 1351-1360. (Pubitemid 27142773)
16. Coolen EJ, Arts IC, Swennen EL, et al. (2008) Simultaneous determination of adenosine triphosphate and its metabolites in human whole blood by RP-HPLC and UV-detection. J Chromatogr B Analyt Technol Biomed Life Sci 864, 43-51.
17. Kichenin K, Decollogne S, Angignard J, et al. (2000) Cardiovascular and pulmonary response to oral administration of ATP in rabbits. J Appl Physiol 88, 1962-1968. (Pubitemid 30453898)
18. Jordan AN, Jurca R, Abraham EH, et al. (2004) Effects of oral ATP supplementation on anaerobic power and muscular strength. Med Sci Sports Exerc 36, 983-990. (Pubitemid 38720780)
19. Yegutkin GG (2008) Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783, 673-694.
20. Strohmeier GR, Lencer WI, Patapoff TW, et al. (1997) Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia. J Clin Invest 99, 2588-2601. (Pubitemid 27259805)
21. Molina-Arcas M, Casado FJ & Pastor-Anglada M (2009) Nucleoside transporter proteins. Curr Vasc Pharmacol 7, 426-434.
22. Fox IH (1981) Metabolic basis for disorders of purine nucleo-tide degradation. Metabolism 30, 616-634. (Pubitemid 11116926)
23. Geren W, Bendich A, Bodansky O, et al. (1950) The fate of uric acid in man. J Biol Chem 183, 11.
24. 0- triphosphate (ATP) in palliative home care. Support Care Cancer 16, 1419-1424.
25. Beijer S, Gielisse EA, Hupperets PS, et al. (2007) Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients. Invest New Drugs 25, 571-579. (Pubitemid 47622115)
26. 0-triphosphate. Drug Dev Res 60, 196-203. (Pubitemid 37351791)
27. Agteresch HJ, Rietveld T, Kerkhofs LG, et al. (2002) Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 20, 371-378. (Pubitemid 34072518)
28. Agteresch HJ, Leij-Halfwerk S, Van Den Berg JW, et al. (2000) Effects of ATP infusion on glucose turnover and gluconeo-genesis in patients with advanced non-small-cell lung cancer. Clin Sci (Lond) 98, 689-695. (Pubitemid 30386432)
29. Leij-Halfwerk S, Agteresch HJ, Sijens PE, et al. (2002) Adeno-sine triphosphate infusion increases liver energy status in advanced lung cancer patients: an in vivo 31P magnetic resonance spectroscopy study. Hepatology 35, 421-424. (Pubitemid 34106384)
30. 0-triphosphate in patients with advanced cancer. Med Pediatr Oncol 27, 165-173. (Pubitemid 26282097)
31. 0-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancer. Invest New Drugs 16, 81-85. (Pubitemid 28379420)
32. Krishnan E, Kwoh CK, Schumacher HR, et al. (2007) Hyper-uricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49, 298-303. (Pubitemid 46143005)
33. Iseki K, Ikemiya Y, Inoue T, et al. (2004) Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 44, 642-650. (Pubitemid 39237608)
34. Dehghan A, Van Hoek M, Sijbrands EJ, et al. (2008) High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31, 361-362. (Pubitemid 351213351)
35. Masuo K, Kawaguchi H, Mikami H, et al. (2003) Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42, 474-480. (Pubitemid 37237341)
36. Amaro S, Planas AM & Chamorro A (2008) Uric acid administration in patients with acute stroke: a novel approach to neuroprotection. Expert Rev Neurother 8, 259-270. (Pubitemid 351281113)
37. Andreadou E, Nikolaou C, Gournaras F, et al. (2009) Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 111, 724-728.
38. Rentzos M, Nikolaou C, Anagnostouli M, et al. (2006) Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 108, 527-531. (Pubitemid 44209214)
39. Cronsteinand BN & Terkeltaub R (2006) The inflammatory process of gout and its treatment. Arthritis Res Ther 8, Suppl. 1, S3.
40. Shi Y, Evans JE & Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521. (Pubitemid 37237047)
41. Armstrong KA, Johnson DW, Campbell SB, et al. (2005) Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients? Transplantation 80, 1565-1571. (Pubitemid 43005867)
42. Johnson RJ, Kang DH, Feig D, et al. (2003) Is there a patho-genetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41, 1183-1190. (Pubitemid 36706063)
43. Wheeler JG, Juzwishin KD, Eiriksdottir G, et al. (2005) Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2, e76.
44. Culleton BF, Larson MG, Kannel WB, et al. (1999) Serum uric acid and risk for cardiovascular disease and death: the Fra-mingham Heart Study. Ann Intern Med 131, 7-13. (Pubitemid 29310011)